All In Biotech

Drug Trial Radar · NCT02144077

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 281 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

281

Actual

Start

Jan 28, 2014

Primary completion

Nov 17, 2015

Study completion Sep 9, 2020

Sponsor

Lead sponsor
Biofrontera Bioscience GmbHIndustry
Sponsor type
Industry
Collaborators
Accovion GmbH
First posted
May 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to test the effectiveness and safety of the medicine Ameluz® (5-aminolevulinic acid) in comparison to methyl-aminolevulinate (MAL), used with photodynamic therapy (PDT), to treat thin, non-aggressive BCC (basal cell carcinoma).

Conditions

  • Basal Cell Carcinoma (BCC)

Interventions

  • BF-200 ALADrug

    Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)

  • methyl-aminolevulinateDrug

    Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Patient Complete Response Rate Assessed 12 Weeks After the Last PDTTime frame: 12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Klinikum Vest GmbH

    Recklinghausen, Westfalen-Lippe, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.